Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | First-in-class anti-CD96 monoclonal antibody alone or with dostarlimab for advanced tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, updates us on the results of a Phase I trial of the first-in-class anti-CD96 monoclonal antibody, GSK6097608, alone or in combination with dostarlimab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors (NCT04446351). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.